The pharmaceutical industry is facing high clinical development costs and declining drug discovery success rates. To stay competitive companies are re-evaluating their drug development process to reduce attrition rates. Biomarkers promises to transform drug discovery, clinical development and molecular diagnostics in the R&D process as effective use of biomarkers at each stage of R&D can improve decision-making, increase clinical trial success rates and productivity.

The 6^th Annual Biomarkers Congress 2011 presented by Oxford Global Conferences provides a first class educational and networking opportunity for over 200 attendees to gain knowledge and insights into the Biomarkers marketplace.

The event explores core topics such as discovery & validation strategies, regulatory issues, the key role of personalised medicine and diagnostics, safety biomarkers and biomarkers within clinical development, as well as the integration of applications and enabling technologies such as genomics, microRNA, systems biology to maximise biomarker identification.

Do not miss out on the opportunity to learn how you can streamline your R&D process and identify potential cost savings through successful biomarker discovery, validation and clinical development. Focus on the integration of technologies & applications to bridge the gap between Discovery, Validation and Development.